Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: An historical account

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 11, 2013, Pages 1547-1556

  Tantry, Udaya S ^a   Mahla, Elisabeth ^b   Gesheff, Martin G ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

clopidogrel; coronary artery disease; dual antiplatelet therapy; high platelet reactivity; P2Y12 receptor; personalized antiplatelet therapy; platelet; platelet function assays

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; CALCIUM; CLOPIDOGREL; CYCLIC AMP; MAGNESIUM; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; ENZYME INHIBITION; EVENT FREE SURVIVAL; HUMAN; LOADING DRUG DOSE; MEASUREMENT; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PHOSPHORYLATION; PLATELET REACTIVITY; PRACTICE GUIDELINE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ADENOSINE DIPHOSPHATE; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS;

EID: 84887368212     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.839382     Document Type: Review

References (66)

1. Schultze M. Ein heizbarer Objecttisch und seineVerwendung bei Untersuchungen des Blutes. Arch. Mikroskop. Anat. 1, 1-14 (1865
2. Osler W. An account of certain organisms occurring in the liquor sanguinis. Proc. R. Soc. Lond. 22, 391-398 (1874
3. Hayem G. Researches sur l'évolution des hématies dans le sang de l'homme, et des vertébrés. Arch. Physiol. (deuxiéme séries) 5, 692-734 (1878
4. Bizzozero J. U ̈ ber einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose undder Blutgerinnung. Arch. Pathol. Anat. Physiol. Klinische Med. 90, 261-332 (1882
5. Coller, BS. Bizzozero and the discovery of the blood platelets. Lancet 323(8380), 804 (1984
6. Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J. Clin. Lab. Invest. 12, 117 (1960
7. Gaarder A, Jonsen J, Laland S, Hellem AJ, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192, 531-532 (1961
8. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927-929 (1962
9. Born GV. Platelets in thrombogenesis: Mechanism and inhibition of platelet aggregation. Ann. R. Coll. Surg. Engl. 36, 200-206 (1965
10. Haslam RJ. Role of adenosine diphosphate in the aggregation of human blood-platelets by thrombin and by fatty acids. Nature 202, 765-768 (1964
11. Kinlough-Rathbone RL, Perry DW, Guccione MA et al. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: Comparison with degranulation by thrombin. Thromb. Haemost. 70, 1019-1023 (1993
12. Born GV. Uptake of adenosine and of adenosine diphosphate by human blood platelets. Nature 206, 1121-1122 (1965
13. Mustard JF, Packham MA. Factors influencing platelet function: Adhesion, release, and aggregation. Pharmacol. Rev. 22, 97-187 (1970
14. Mills DC, Smith JB. The control of platelet responsiveness by agents that influence cyclic AMP metabolism. Ann. N. Y. Acad. Sci. 201, 391-399
15. Macfarlane DE, Mills DC, Srivastava PC. Binding of 2-Azidoadenosine [beta-32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 21, 544-549 (1982
16. Macfarlane DE, Srivastava PC, Mills DC. 2-Methylthioadenosine[beta-32P] diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J. Clin. Invest. 71, 420-428 (1983
17. Gachet C, Cattaneo M, Ohlmann P et al. Purinoceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br. J. Haematol. 91, 434-444 (1995
18. Nurden P, Savi P, Heilmann E et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J. Clin. Invest. 95, 1612-1622 (1995
19. Cristalli G, Mills DCB. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem. J. 291, 875-881 (1993
20. MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J. Biol. Chem. 271, 2879-2881 (1996
21. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024-2029 (1998
22. Cattaneo M. The platelet P2 receptors. In: Platelets (2nd Edition). Michelson AD (Ed.). Elsevier, New York, 201-210 (2007
23. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3, 85-92 (2005
24. Ohlmann P, Laugwitz K-L, Nürnberg B et al. The human platelet ADP receptor activates Gi2 proteins. Biochem. J. 312, 775-779 (1995
25. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113, 340-345 (2004
26. Sano T, Motomiya T, Yamazaki H et al. Enhancement of platelet sensitivity to ADP-Aggregation by isometric exercise in arteriosclerosis patients and its prevention. Thromb. Haemost. 37, 329-338 (1977
27. Gurbel PA, Bliden KP, Hayes KM et al. Platelet activation in myocardial ischemic syndromes. Expert Rev. Cardiovasc. Ther. 2, 535-545 (2004
28. Trip MD, Cats VM, van Capelle FJ et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. 322, 1549-1554 (1990
29. Hirsh J. Hyperactive platelets and complications of coronary artery disease. N. Engl. J. Med. 316, 1543-1544 (1987
30. Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125, 1276-87, discussion 1287 (2012
31. Järemo P, Lindahl TL, Fransson SG et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med. 252, 233-238 (2002
32. Gurbel PA, Malinin AI, Callahan KP et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am. J. Cardiol. 90, 312-315 (2002
33. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003
34. Bonello L, Tantry US, Marcucci R et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010
35. Müller I, Besta F, Schulz C et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89, 783-787 (2003
36. Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 59, 295-302 (2003
37. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004
38. Samara WM, Bliden KP, Tantry US et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res. 115, 89-94 (2005
39. Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POSTSTENTING Study. J. Am. Coll. Cardiol. 46, 1820-1826 (2005
40. Gurbel PA, Bliden KP, Samara W et al. The clopidogrel Resistance and Stent Thrombosis (CREST) study. J. Am. Coll. Cardiol. 46, 1827-1832 (2005
41. Bliden KP, DiChiara J, Tantry US et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49, 657-666 (2007
42. Brar SS, ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-Analysis of individual participant data. J. Am. Coll. Cardiol. 58, 1945-1954 (2011
43. Stone GW. Assessment of dual antiplatelet therapy with drug-eluting stents a large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation. Presented at: TCT. San Francisco, 27 October-1 November 2011 and Florida, USA, 22-26 October 2012
44. Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57, 2474-2483 (2011
45. Sibbing D, Schulz S, Braun S et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8, 250-256 (2010
46. Gurbel PA, Bliden KP, Navickas IA et al. Adenosine diphosphate-induced plateletfibrin clot strength: A new thrombelastographic indicator of long-Term poststenting ischemic events. Am. Heart J. 160, 346-354 (2010
47. Bonello L, Mancini J, Pansieri M et al. Relationship between post-Treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J. Thromb. Haemost. 10, 1999-2005 (2012
48. Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57, 2474-2483 (2011
49. Gurbel PA, Ohman EM, Jeong YH, Tantry US. Toward a therapeutic window for antiplatelet therapy in the elderly. Eur. Heart J. 33, 1187-1189 (2012
50. Jeong YH, Bliden KP, Tantry US, Gurbel PA Do East Asians have different hypercoagulable states compared with Western population? Am. Heart J. 162, e19-e20 (2011
51. Price MJ, Berger PB, Teirstein PS et al. GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 305, 1097-1105 (2011
52. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008
53. Bonello L, Camoin-Jau L, Armero S et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103, 5-10 (2009
54. Campo G, Fileti L, de Cesare N et al. on behalf of the (3T/2R) investigators. Long-Term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention J. Am. Coll. Cardiol. 56, 1447-1455 (2010
55. Cuisset T, Frere C, Quilici J et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study. JACC Cardiovasc. Interv. 1, 649-653 (2008
56. Mega JL, Hochholzer W, Frelinger AL III et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011
57. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a verifynow P2Y12 assay: Impact on thrombosis and safety (GRAVITAS) trial. Circulation 124, 1132-1137 (2011
58. Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59, 2159-2164 (2012
59. Collet JP, Cuisset T, Rangé G et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100-2109 (2012
60. Gurbel PA, Erlinge D, Ohman EM et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy. JAMA 308, 1785-1794
61. Reny JL, Berdagué P, Poncet A et al. Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: Results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 125, 3201-3210
62. Mahla E, Suarez TA, Bliden KP et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-Treated patients undergoing coronary artery bypass graft surgery: The timing based on platelet function strategy to reduce clopidogrel-Associated bleeding related to CABG (TARGET-CABG) study. Circ. Cardiovasc. Interv. 5, 261-269 (2012
63. Jneid H, Anderson JL, Wright RS et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American college of cardiology foundation/ American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 60, 645-681 (2012
64. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur. Heart J. 32, 2999-3054 (2011
65. Levine GN, Bates ER, Blankenship JC et al. American college of cardiology foundation; American heart association task force on practice guidelines; society for cardiovascular angiography and interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J. Am. Coll. Cardiol. 58, e44-122 (2011
66. Ferraris VA, Saha SP, Oestreich JH et al. Society of Thoracic Surgeons. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann. Thorac. Surg. 94, 1761-1781 (2012